Skip to content
Study details
Enrolling now

Feasibility Study of Oral Ketamine Versus Placebo for the Treatment of Anxiety in Patients With Pancreatic Cancer

Cedars-Sinai Medical Center
NCT IDNCT05086250ClinicalTrials.gov data as of Apr 2026
Phase

EARLY_PHASE1

Target enrollment

20

Study length

about 4.2 years

Ages

18+

Locations

1 site in CA

About this study

This trial is testing whether oral ketamine or a placebo can help reduce anxiety in people with pancreatic cancer. The goal is to see if it's possible to enroll enough patients and have them follow the treatment plan. Researchers will also look at safety, tolerability, and how ketamine/placebo affects anxiety symptoms and other health measures.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take Ketamine
  • 2.Take Placebo
PhaseEARLY_Phase 1
DrugKetamine

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low14%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

ketamine (NMDA receptor antagonist; induces dissociative anesthesia and analgesia)

Endpoints

Secondary: To investigate the safety of oral ketamine in patients with pancreatic cancer and anxiety, which will be assessed by the number of adverse events related to study treatment per CTCAE v.5., To investigate the tolerability of oral ketamine in patients with pancreatic cancer and anxiety, which will be measured by patient-reported Ketamine Adverse Symptom Checklist and Impact scores.

Body systems

Psychiatry / Mental Health, Oncology